SCHEMBL2335264

SCHEMBL2335264

COc1cnc(Cl)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30971909 1.00
SCHEMBL3138241 0.84 SIRT6 (0.56)
SCHEMBL22518716 0.76 MAPT (0.40)
SCHEMBL21807894 0.76 PLAU (0.40)
SCHEMBL22518721 0.75 ALDH1A1 (0.39)
SCHEMBL15577926 0.74 PLAU (0.33)
SCHEMBL933680 0.74
SCHEMBL18994460 0.73 IDO1 (0.34)
SCHEMBL18994454 0.73 GABRP (0.38)
SCHEMBL27932250 0.73 ALDH1A1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101687860-A Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain ASTRAZENECA AB 2010-03-31 CN claimed
US-20250326754-A1 DNA-PK Inhibitor Compounds and Uses Thereof ADMARE THERAPEUTICS SOC (CA) 2025-10-23 US disclosed
US-20250230172-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2025-07-17 US disclosed
US-12275728-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2025-04-15 US disclosed
EP-4522620-A1 DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF Admare Therapeutics Society (CA) 2025-03-19 EP disclosed
US-20250074895-A1 CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME BLUEPRINT MEDICINES CORPORATION 2025-03-06 US disclosed
US-12180205-B2 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2024-12-31 US disclosed
US-20240308995-A1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. 2024-09-19 US disclosed
EP-4416152-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-08-21 EP disclosed
CN-113166137-B O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranoside enzyme inhibitors 比奥根MA公司 2024-08-16 CN disclosed
US-20110245227-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2011-10-06 US disclosed
EP-2170864-B1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2011-09-14 EP disclosed
US-8003796-B2 Pyridone GPR119 G protein-coupled receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-23 US disclosed
CN-101001851-B Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC) ASTELLAS PHARMA INC 2011-04-20 CN disclosed
CN-101801957-A Pyridone GPR 119 g protein-coupled receptor agonists BRISTOL MYERS SQUIBB CO 2010-08-11 CN disclosed
EP-2170864-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS Bristol-Myers Squibb Company (US) 2010-04-07 EP disclosed
CN-101687860-A Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain ASTRAZENECA AB 2010-03-31 CN disclosed
US-20090023702-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY 2009-01-22 US disclosed
WO-2009012275-A1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-01-22 WO disclosed
CN-101001851-A Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC) ASTELLAS PHARMA INC (JP) 2007-07-18 CN disclosed